责任编辑：卢昱君 客户端 长江生命科技（00775）现涨超4%，截至发稿，股价上涨3.57%，报0.87港元，成交额3550.52万港元。 长江生命科技公布，成立科学顾问委员会，由来自学术界、临床研究及业界的独立专家所组成，成员包 括前食物及卫生局局长高永文、港大临床教授及癌症医学中心总监许漪雯，及中大肿瘤学系系主任莫树 锦等。 集团表示，委员会属策略性组织，并将提供科学、临床及规管指引，以支持长江生命科技的科研项目全 速前进，包括多项正准备展开临床研究的治疗性癌症疫苗。另外，科学顾问委员会将提供专业资源，以 助公司应对日趋繁复的环球药物研发环境、 缓减风险，以及加快获得监管批核和接触病患者的途径。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 长江生命科技（00775）现涨超4%，截至发稿，股价上涨3.57%，报0.87港元，成交额3550.52万港元。 长江生命科技公布，成立科学顾问委员会，由来自学术界、临床研究及业界的独立专家所组成，成员包 括前食物及卫生局局长高永文、港大临床教授及癌症医学中心总监许漪雯，及 ...

集团表示，委员会属策略性组织，并将提供科学、临床及规管指引，以支持长江生命科技的科研项目全 速前进，包括多项正准备展开临床研究的治疗性癌症疫苗。另外，科学顾问委员会将提供专业资源，以 助公司应对日趋繁复的环球药物研发环境、缓减风险，以及加快获得监管批核和接触病患者的途径。 长江生命科技(00775)现涨超4%，截至发稿，涨3.57%，报0.87港元，成交额3170.98万港元。 消息面上，长江生命科技公布，成立科学顾问委员会，由来自学术界、临床研究及业界的独立专家所组 成，成员包括前食物及卫生局局长高永文、港大临床教授及癌症医学中心总监许漪雯，及中大肿瘤学系 系主任莫树锦等。 ...

智通财经APP获悉，长江生命科技(00775)现涨超4%，截至发稿，涨3.57%，报0.87港元，成交额3170.98 万港元。 集团表示，委员会属策略性组织，并将提供科学、临床及规管指引，以支持长江生命科技的科研项目全 速前进，包括多项正准备展开临床研究的治疗性癌症疫苗。另外，科学顾问委员会将提供专业资源，以 助公司应对日趋繁复的环球药物研发环境、 缓减风险，以及加快获得监管批核和接触病患者的途径。 消息面上，长江生命科技公布，成立科学顾问委员会，由来自学术界、临床研究及业界的独立专家所组 成，成员包括前食物及卫生局局长高永文、港大临床教授及癌症医学中心总监许漪雯，及中大肿瘤学系 系主任莫树锦等。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | 本月底法定/註冊股本總額： HKD 1,500,000,000 第 1 頁 共 10 頁 v 1.2.0 截至月份: 2026年1月31日 狀 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 9,611,072,400 | | 0 | | 9,611,072,400 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 9,611,072,400 | | 0 | | 9,611,072,400 | 公司名稱: 長江生命科技集團有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變 ...

Core Viewpoint - Changjiang Life Sciences Technology (0775.HK) announced positive interim results from the ongoing Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain (CINP) conducted by its biopharmaceutical subsidiary Dogwood Therapeutics (DWTX.US) [1] Group 1 - The independent statistical review committee analyzed data from 97 patients who completed treatment and found a positive difference in pain improvement between patients receiving Halneuron and those receiving a placebo [1] - The current recruitment trend for the Phase 2b trial is expected to provide approximately 80% to 85% statistical power to detect differences in Halneuron treatment [1] - Dogwood anticipates obtaining preliminary results by the third quarter of 2026 based on the current recruitment pace and interim assessment results [1] Group 2 - The results of the independent interim analysis have strengthened the company's confidence that Halneuron could provide a treatment option for CINP patients, where standard therapies are currently lacking [1] - The analysis supports the strategic vision of the group to develop pain and related condition medications through Dogwood [1]

Group 1 - The core announcement is regarding the positive interim results from the ongoing Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain (CINP) conducted by Dogwood Therapeutics, Inc. [1] - The study involved 97 patients who completed treatment, showing a significant difference in pain improvement between those receiving Halneuron and those on placebo [1]. - The average duration of CINP among the study participants was 5 years, with 67% of patients concurrently on stable doses of other chronic pain medications [2]. Group 2 - The overall dropout rate for the study was approximately 4.4%, which is significantly lower than the dropout rates of other FDA-approved chronic pain medications [2]. - Dogwood anticipates obtaining preliminary results by Q3 2026, based on the current recruitment pace and interim analysis results, with an expected statistical power of 80% to 85% to detect treatment differences [2]. - Dogwood is a development-stage biopharmaceutical company focused on developing new drugs for pain relief and neuropathic symptoms, holding approximately 83% indirect equity interest in Dogwood [2].

Group 1 - The core announcement is regarding the positive interim results from the ongoing Phase 2b study of Halneuron for chemotherapy-induced neuropathic pain (CINP) conducted by Dogwood Therapeutics, Inc. [1] - The study involved 97 patients who completed treatment, showing a significant difference in pain improvement between those receiving Halneuron and those on placebo [1] - Dogwood emphasizes that the preliminary evidence of Halneuron's effectiveness is noteworthy, especially considering that 67% of the patients were concurrently on stable doses of other chronic pain medications [2] Group 2 - The overall dropout rate for the study was approximately 4.4%, which is significantly lower than the dropout rates of other FDA-approved chronic pain medications [2] - Despite being in a blinded phase, Dogwood believes the findings reaffirm the encouraging safety and tolerability observed in previous clinical trials of Halneuron [2] - The company anticipates obtaining preliminary results by Q3 2026, with the current study expected to provide about 80% to 85% statistical power to detect treatment differences [2] Group 3 - Dogwood Therapeutics is a development-stage biopharmaceutical company registered in Delaware and listed on the NASDAQ under the ticker DWTX, focusing on developing new drugs for alleviating pain and neurological discomfort [2] - The company currently holds approximately 83% indirect equity interest in Dogwood [2]

Core Insights - Changjiang Life Sciences Technology (00775.HK) announced the latest developments regarding its investment in Dogwood Therapeutics, Inc. (DWTX), a biopharmaceutical company focused on developing new drugs for pain relief and neuropathic symptoms, holding approximately 83% indirect equity in Dogwood [1] Group 1: Clinical Trial Results - Dogwood reported positive mid-term analysis results from its ongoing Phase 2b study of Halneuron® for chemotherapy-induced neuropathic pain (CINP), with 97 patients completing treatment [1] - The independent statistical review committee found a significant difference in pain improvement between patients treated with Halneuron® and those receiving a placebo during the four-week study [1] Group 2: Patient Demographics and Treatment Context - The average duration of CINP among patients in the mid-term analysis was 5 years, with 67% of eligible patients concurrently receiving stable doses of other chronic pain medications, including pregabalin, gabapentin, duloxetine, and opioids [2] - The overall dropout rate for the study was approximately 4.4%, significantly lower than the dropout rates of other FDA-approved chronic pain medications [2] Group 3: Future Expectations - Dogwood anticipates obtaining preliminary results from the Phase 2b trial by the third quarter of 2026, based on current recruitment speed and mid-term evaluation results [2] - The ongoing study is expected to provide approximately 80% to 85% statistical power to detect treatment differences for Halneuron® [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 Dogwood 表示Halneuron® 治療效果的初步證據值得關注，基於中期分析群組中患者平均 CINP 患期為 5 年，且 67% 符合入組標準的患者同時接受其他慢性疼痛藥物的穩定劑量治 療，包括普瑞巴林（pregabalin）、加巴噴丁（gabapentin）、度洛西汀（duloxetine）及 類鴉片（opioids）藥物。此外，該研究的整體退出率約4.4%，遠低於其他美國食品及 藥物管理局批准的慢性疼痛藥物的退出率。儘管目前仍處於盲法階段，惟 Dogwood認為 是項發現再次證明 Halneuron® 在先前臨床試驗中觀察所得令人鼓舞的安全性及耐受性。 根據目前第二b 期試驗的招募速度及中期評估結果，Dogwood 仍預計將在二零二六年第三 季內獲得初步結果。目前的研究預計將提供約 80% 至 85% 的統計功效以檢測Halneuron® 的治療差異。 務請注意，Halneuron® 目前仍處 ...